📊 ELAN Key Takeaways
Is ELAN a Good Investment? Thesis Analysis
Elanco faces significant profitability headwinds despite 6.2% revenue growth, with negative operating income (-$224M) and net losses (-$232M) indicating operational challenges that offset top-line expansion. Strong cash generation ($284M FCF) and solid balance sheet metrics provide a cushion, but persistent negative margins and poor return metrics signal fundamental business deterioration that requires immediate operational improvement.
Why Buy ELAN? Key Strengths
- Revenue growth of 6.2% YoY demonstrates market demand and customer retention in pharmaceutical preparations
- Strong free cash flow generation of $284M (6.0% FCF margin) despite losses shows underlying business cash conversion
- Healthy balance sheet with 2.17x current ratio and manageable 0.57x debt-to-equity, providing financial flexibility
ELAN Investment Risks to Consider
- Negative operating margin of -4.8% and net margin of -4.9% indicate structural profitability issues despite 55% gross margins
- Deteriorating earnings with net income declining 168.6% YoY to -$232M, suggesting operational cost structure is unsustainable
- Negative interest coverage ratio of -1.2x raises debt servicing concerns if operating performance does not improve soon
- Negative ROE (-3.5%) and ROA (-1.7%) demonstrate value destruction despite asset base of $13.4B
Key Metrics to Watch
- Operating margin trend - must return to positive to validate business model viability
- Net income recovery path and timeline to profitability
- Operating cash flow sustainability and free cash flow conversion as losses continue
- SG&A expense management and gross margin stability
- Long-term debt reduction progress given current operating losses
ELAN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.17x current ratio provides a solid financial cushion.
ELAN Profitability Ratios
ELAN vs Healthcare Sector
How Elanco Animal Health Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ELAN Overvalued or Undervalued?
Based on fundamental analysis, Elanco Animal Health Inc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ELAN Balance Sheet & Liquidity
ELAN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Elanco Animal Health Inc's revenue has remained relatively flat over the 5-year period, with a 1% decline. The most recent EPS of $-2.50 indicates the company is currently unprofitable.
ELAN Growth Metrics (YoY)
ELAN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.0B | $11.0M | $-0.07 |
| Q2 2025 | $1.2B | $11.0M | $0.02 |
| Q1 2025 | $1.2B | $32.0M | $0.06 |
| Q3 2024 | $1.0B | $32.0M | $0.70 |
| Q2 2024 | $1.1B | $6.0M | $0.01 |
| Q1 2024 | $1.2B | $32.0M | $0.06 |
| Q3 2023 | $1.0B | -$10.0M | $-0.05 |
| Q2 2023 | $1.1B | $6.0M | $0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ELAN Capital Allocation
ELAN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Elanco Animal Health Inc (CIK: 0001739104)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 10, 2026 | 4 | xslF345X05/form4-03102026_080349.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/form4-03102026_080323.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/form4-03102026_080341.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/form4-03102026_080306.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/form4-03052026_090349.xml | View → |
❓ Frequently Asked Questions about ELAN
What is the AI rating for ELAN?
Elanco Animal Health Inc (ELAN) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELAN's key strengths?
Claude: Revenue growth of 6.2% YoY demonstrates market demand and customer retention in pharmaceutical preparations. Strong free cash flow generation of $284M (6.0% FCF margin) despite losses shows underlying business cash conversion.
What are the risks of investing in ELAN?
Claude: Negative operating margin of -4.8% and net margin of -4.9% indicate structural profitability issues despite 55% gross margins. Deteriorating earnings with net income declining 168.6% YoY to -$232M, suggesting operational cost structure is unsustainable.
What is ELAN's revenue and growth?
Elanco Animal Health Inc reported revenue of $4.7B.
Does ELAN pay dividends?
Elanco Animal Health Inc does not currently pay dividends.
Where can I find ELAN SEC filings?
Official SEC filings for Elanco Animal Health Inc (CIK: 0001739104) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELAN's EPS?
Elanco Animal Health Inc has a diluted EPS of $-0.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELAN a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Elanco Animal Health Inc has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ELAN stock overvalued or undervalued?
Valuation metrics for ELAN: ROE of -3.5% (sector avg: 15%), net margin of -4.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ELAN stock in 2026?
Our dual AI analysis gives Elanco Animal Health Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELAN's free cash flow?
Elanco Animal Health Inc's operating cash flow is $560.0M, with capital expenditures of $276.0M. FCF margin is 6.0%.
How does ELAN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4.9% (avg: 12%), ROE -3.5% (avg: 15%), current ratio 2.17 (avg: 2).